The 36-month beta value for CNTX is at 2.10. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNTX is 59.22M, and currently, shorts hold a 1.67% of that float. The average trading volume for CNTX on January 10, 2025 was 503.89K shares.
CNTX) stock’s latest price update
The stock price of Context Therapeutics Inc (NASDAQ: CNTX) has jumped by 11.01 compared to previous close of 1.09. Despite this, the company has seen a gain of 15.24% in its stock price over the last five trading days. globenewswire.com reported 2024-11-06 that Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody
CNTX’s Market Performance
Context Therapeutics Inc (CNTX) has seen a 15.24% rise in stock performance for the week, with a -19.33% decline in the past month and a -34.95% plunge in the past quarter. The volatility ratio for the week is 16.01%, and the volatility levels for the past 30 days are at 12.72% for CNTX. The simple moving average for the past 20 days is -0.25% for CNTX’s stock, with a -35.04% simple moving average for the past 200 days.
Analysts’ Opinion of CNTX
Many brokerage firms have already submitted their reports for CNTX stocks, with JMP Securities repeating the rating for CNTX by listing it as a “Mkt Outperform.” The predicted price for CNTX in the upcoming period, according to JMP Securities is $4 based on the research report published on January 08, 2025 of the current year 2025.
D. Boral Capital, on the other hand, stated in their research note that they expect to see CNTX reach a price target of $9. The rating they have provided for CNTX stocks is “Buy” according to the report published on November 25th, 2024.
Piper Sandler gave a rating of “Overweight” to CNTX, setting the target price at $4.50 in the report published on May 16th of the previous year.
CNTX Trading at -23.22% from the 50-Day Moving Average
After a stumble in the market that brought CNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.00% of loss for the given period.
Volatility was left at 12.72%, however, over the last 30 days, the volatility rate increased by 16.01%, as shares sank -19.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.29% lower at present.
During the last 5 trading sessions, CNTX rose by +15.24%, which changed the moving average for the period of 200-days by +3.86% in comparison to the 20-day moving average, which settled at $1.2130. In addition, Context Therapeutics Inc saw 15.24% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CNTX
Current profitability levels for the company are sitting at:
- -1717.32 for the present operating margin
- 0.59 for the gross margin
The net margin for Context Therapeutics Inc stands at -1590.97. The total capital return value is set at -0.39. Equity return is now at value -58.98, with -55.16 for asset returns.
Currently, EBITDA for the company is -25.06 million with net debt to EBITDA at 2.6. When we switch over and look at the enterprise to sales, we see a ratio of 326.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 36.91.
Conclusion
In conclusion, Context Therapeutics Inc (CNTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
